News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2011

Epigenomics AG to Suggest Reduction of Share Capital and 5:1 Reverse Stock Split at Upcoming AGM

18.05.2011 | 110518_Epigenomics_AG_press_release_AGM Berlin, Germany, May 18, 2011 Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, today issued invitations to its Annual General Shareholders’ Meeting scheduled for June 28, 2011.

Read more

Epigenomics AG Releases Q1 Results

11.05.2011 | 110511_Press_release_Q1_Results_ Berlin, Germany, May 11, 2011 – Epigenomics AG (Frankfurt Prime Standard: ECX) today reports its Q1 financials for the period ended 31 March 2011.

Read more

Epigenomics AG: Screening More People for Colorectal Cancer with Septin9 Blood Tests Could Provide Medical Benefit and Be Cost-Effective

Health economic analysis in favor of Septin9 testing presented by renowned Stanford University researcher at Digestive Disease Week 2011

Read more

Epigenomics AG: Life Technologies to Supply Crucial Components for Second-Generation Colorectal Cancer Blood Test

Berlin, Germany, and Seattle, WA, U.S.A., May 6, 2011 Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnosis company, today announced the signing of a supply agreement with Life Technologies Corporation, a global provider of innovative life science solutions. As the Original Equipment Manufacturer (OEM) Life Technologies will supply its Dynabeads® MyOne™ SILANE and buffers […]

Read more

Epigenomics AG: Noel Doheny Appointed as New CEO of US-Subsidiary Epigenomics Inc.

20.04.2011 | 110420_New_US_CEO_EN_final Berlin, Germany, and Seattle, WA, USA, April 20, 2011 Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer diagnosis company, today announced the appointment of Noel Doheny as the new Chief Executive Officer (CEO) of its subsidiary Epigenomics Inc. in Seattle, WA, USA, reporting to Geert Nygaard, CEO of Epigenomics AG. Mr. Doheny […]

Read more

Epigenomics AG: Full Year Results for the Year Ended 31 December 2010

 Continuing to build European market and expanding beyond. • Focus 2010/2011 on U.S. product development and FDA submission. • Launch of Epi proColon® 2.0 in Europe planned for 2011

Read more